Pergolide Mesylate: New Therapy for Parkinson Disease
Authors: CAROLINE M. TANNER
Journal: Annals of Internal Medicine (1982)

Editorials1 April 1982Pergolide Mesylate: New Therapy for Parkinson DiseaseCAROLINE M. TANNER, M.D., HAROLD L. KLAWANS, M.D.CAROLINE M. TANNER, M.D.Search for more papers by this author, HAROLD L. KLAWANS, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-96-4-522 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe side effects of chronic levodopa therapy are rarely as disabling as Parkinson disease itself. Many patients, however, after years of levodopa therapy at doses needed to control parkinsonism, are disabled by dyskinesias or psychoses. Others experience a progressive shortening of levodopa's effect (reduced "on" time) after each dose or sudden, freezing episodes (the "on/off" phenomenon) not related to dose. These therapeutic difficulties have encouraged a search for other antiparkinsonian agents. Because the primary neurohumoral defect in patients with Parkinson disease is loss of striatal dopamine, much research has focused on direct-acting dopamine agonists.Pergolide mesylate, a synthetic cousin of...References1. CAPOREL L. Ergotism: the Satan loosed in Salem? Science. 1976;192:21-6. CrossrefMedlineGoogle Scholar2. KLEINBERGLIEBERMANTODDGREISINGNEOPHYIDESKUPERSMITH DAJJAM. Pergolide mesylate: a potent day-long inhibitor of prolactin in rhesus monkeys, and patients with Parkinson's disease. J Clin Endocrinol Metab. 1980;51:152-4. CrossrefMedlineGoogle Scholar3. RINNE U. Dopaminergic agonists in the treatment of Parkinson's disease. In: Abstracts, 12th World Congress of Neurology. Kyoto, Japan, September 20-25, 1981. Amsterdam: Excepta Medica; 1981:133. Google Scholar4. LIEBERMANGOLDSTEINLEIBOWITZ AMM. Treatment of advanced Parkinson disease with pergolide. Neurology. 1981;31:675-82. CrossrefMedlineGoogle Scholar5. CALNEWARD DC. Current concepts on the treatment of Parkinson's disease—the use of dopamine agonists. In: Abstracts. 12th World Congress of Neurology. Kyoto, Japan, September 20-25, 1981. Amsterdam: Excerpta Medica; 1981: 134. Google Scholar6. PARKESSCHACHTERQUINNLANGHOROWSKI JMNAR. Bromocriptine, lisuride and pergolide in the treatment of Parkinson's disease. In: Abstracts. 12th World Congress of Neurology, Kyoto, Japan, September 20-25, 1981. Amsterdam: Excerpta Medica; 1981:330. Google Scholar7. KLAWANSTANNERGOETZGLATTNAUSIEDAWEINER HCCSPW. Pergolide mesylate therapy in Parkinson disease: report of a three month trial in 20 patients. Neurology. 1981;31:133. Abstract. Google Scholar8. YAHR M. Treatment of Parkinson's disease. In: Abstracts. 12th World Congress of Neurology. Kyoto, Japan, September 20-25, 1981. Amsterdam: Excerpta Medica; 1981: 134-5. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: CAROLINE M. TANNER, M.D.; HAROLD L. KLAWANS, M.D.Affiliations: Departments of Neurological Sciences and Pharmacology Rush-Presbyterian-St. Luke's Medical Center Chicago, Illinois PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPergolide in the Treatment of Parkinson’s Disease 1 April 1982Volume 96, Issue 4Page: 522-523KeywordsDopamineLevodopaParkinson diseasePsychoses ePublished: 1 December 2008 Issue Published: 1 April 1982 PDF downloadLoading ...